Laura Stoppel

Laura Stoppel, PhD, is a Principal on the Investment Team at RA Capital Management. Laura works on both public and private investments and serves as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, and Acumen Pharmaceuticals. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. Her graduate research investigated synaptic translation in syndromic autism.